CAVHANZA Drug Patent Profile

When do Cavhanza patents expire, and what generic alternatives are available?

Cavhanza is a drug marketed by Flex Pharma and is included in one NDA. There are four patents protecting this drug.

This drug has thirteen patent family members in six countries.

The generic ingredient in CAVHANZA is nilotinib. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nilotinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Cavhanza

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 30, 2041. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for CAVHANZA

International Patents:	13
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in CAVHANZA?	CAVHANZA excipients list
DailyMed Link:	CAVHANZA at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for CAVHANZA

Constraining patent/regulatory exclusivity:

11,559,485

NDA:

217379

Dosage:

TABLET, ORALLY DISINTEGRATING;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for CAVHANZA

CAVHANZA is protected by six US patents.

This potential generic entry date is based on patent 11,559,485.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Flex Pharma	CAVHANZA	nilotinib	TABLET, ORALLY DISINTEGRATING;ORAL	217379-001	May 29, 2026		RX	Yes	No	12,016,861
Flex Pharma	CAVHANZA	nilotinib	TABLET, ORALLY DISINTEGRATING;ORAL	217379-002	May 29, 2026		RX	Yes	Yes	12,016,861
Flex Pharma	CAVHANZA	nilotinib	TABLET, ORALLY DISINTEGRATING;ORAL	217379-002	May 29, 2026		RX	Yes	Yes	11,559,485		Y

International Patents for CAVHANZA

When does loss-of-exclusivity occur for CAVHANZA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

European Patent Office

Israel

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering CAVHANZA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2021212258	Amorphous nilotinib microparticles and uses thereof
Australia	2026204369	Amorphous nilotinib microparticles and uses thereof
Canada	3168680	MICROPARTICULES DE NILOTINIB AMORPHE ET LEURS UTILISATIONS (AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOF)

CAVHANZA (cannabidiol; “Cavhanza”) Market Dynamics and Financial Trajectory: Pricing, Uptake, Exclusivity, and Competitive Risk

Last updated: July 9, 2026

CAVHANZA’s financial trajectory is governed by three variables: (1) FDA approval status and labeled patient population size, (2) payor coverage and net pricing versus competing cannabinoids, and (3) how quickly CAVHANZA’s branded price and contracting terms clear the “step therapy and prior authorization” barrier common to CNS cannabinoid products. Without a confirmed, authoritative FDA label and Orange Book exclusivity/Patent Package for “CAVHANZA” by active ingredient and NDA/BLA number, CAVHANZA cannot be tied to a defensible sales forecast, launch timeline, or legal exclusivity map.

What is CAVHANZA and how does the labeled indication drive market size?

Featured answer: CAVHANZA’s market is determined by its exact FDA-labeled indication(s), route(s), dose forms, and whether it targets rare epilepsy syndromes, spasticity, or other CNS endpoints versus symptom management. Labeled scope dictates eligible prescribers, payer policies, and expected patient count.

Which active ingredient and dosage form matter for adoption economics?

CAVHANZA market dynamics differ materially depending on whether it is:

• A cannabidiol (CBD) pharmaceutical product with standardized dosing, or
• A cannabis-derived or cannabinoid combination product with additional actives.

Key commercial implications:

• CBD-like products with epilepsy labels typically face high utilization management (prior authorization, quantity limits) and payer-by-payer reimbursement negotiation.
• CNS cannabinoid products with broader symptom targets often expand addressable populations but increase contracting complexity and clinical comparability scrutiny.

What prescriber behavior shapes early uptake?

Uptake depends on:

• Neurology or epilepsy specialist concentration in early scripts.
• Hospital formularies versus community prescriber behavior.
• Case mix and how frequently patients meet label criteria.

How do pricing and reimbursement dynamics typically work for cannabinoid pharmaceuticals like CAVHANZA?

Featured answer: Net price for cannabinoid CNS products usually trades off list price against payer access through rebates, step therapy criteria, and prior authorization.

What payor coverage pressure determines net revenue per patient?

Cavhanza’s net revenue path is typically shaped by:

• Formulary tier placement (preferred vs non-preferred).
• Medical vs pharmacy benefit assignment (rare but can alter reimbursement velocity).
• Prior authorization triggers (concomitant therapy history, diagnostic confirmation, severity grading).
• Required documentation and renewal cycles.

What contract structures most affect financial trajectory?

Common mechanisms:

• Rebate escalators tied to volume thresholds.
• Patient access programs (discounts tied to coverage approvals).
• Outcomes-based rebates for defined clinical endpoints, where payers require evidence of response durability.

How does competition affect achievable net price?

Net price erosion accelerates when:

• A lower-cost cannabinoid enters the market with comparable endpoints.
• Payers implement therapeutic substitution or preferred-agent policies.
• Generic-like products compete via compounding, unless the FDA product is strongly differentiated by formulation and dosing uniformity.

When does CAVHANZA lose exclusivity and how does that shift the commercial curve?

Featured answer: The exclusivity release schedule (patent expiration and regulatory exclusivities such as 5-year/3-year exclusivity where applicable, plus pediatric extensions) determines whether the sales curve bends down gradually through competition or drops sharply with first authorized entrant.

What expiration and exclusivity events usually govern cannabinoid CNS product risk?

For drug products, exclusivity and patent cliffs typically include:

• Composition-of-matter protection for the active ingredient/formulation.
• Method-of-use patents covering labeled indications.
• Formulation and manufacturing patents that block “design-around” generics or low-cost replacements.
• Exclusivity extensions for pediatric studies or additional clinical data.

Critical constraint: No Orange Book patent/exclusivity listing for “CAVHANZA” by NDA/BLA or active ingredient can be produced from the information provided. Without that, a reliable exclusivity and generic entry timeline cannot be stated.

What patents protect CAVHANZA and how strong is the patent estate?

Featured answer: Patent strength for cannabinoid pharmaceuticals is usually concentrated in composition-of-matter and formulation claims, with secondary coverage in method-of-use and manufacturing processes.

Which patent types usually matter most to generic and authorized-entrant risk?

• Composition-of-matter: blocks direct cannabidiol or defined cannabinoid formulations.
• Formulation: blocks specific ratios, particle sizes/dispersion, solubilizers, or delivery-system characteristics.
• Method-of-use: blocks switching to the same endpoint via a new route or dosing regimen.
• Manufacturing: blocks specific process controls tied to stability and bioavailability.

How does the presence of multiple formulation patents change litigation leverage?

If the patent estate includes layered formulation and process patents, entrants face:

• Longer Paragraph IV litigation runway.
• More settlement opportunities with staggered licensing.
• Higher likelihood of “authorized generic” or non-literal settlements rather than pure generic entry.

Critical constraint: Patent numbers, assignees, jurisdictions, expiration dates, and litigation status for CAVHANZA are not provided, so the patent estate cannot be mapped to a quantified strength score.

What generic entry risks exist for CAVHANZA?

Featured answer: Generic entry risk depends on (1) whether the active ingredient is protected by composition-of-matter claims, (2) whether method-of-use patents prevent carving out labeled endpoints, and (3) whether formulation patents block bioequivalent substitutes.

Paragraph IV landscape and settlement-driven outcomes

For high-friction CNS products, generic entrants often attempt:

• Narrow Paragraph IV challenges to specific patents.
• Design-around formulation changes to avoid formulation claims.
• Carve-out labeling strategies to avoid method-of-use infringement.

Biosimilar risk is not the main issue unless CAVHANZA is biologic

CAVHANZA is not described as a biologic in the prompt. Biosimilar risk models do not apply unless CAVHANZA is a therapeutic protein or antibody product.

How does CAVHANZA compare with competing cannabinoid drugs in market dynamics?

Featured answer: Competitive positioning for cannabinoid pharmaceuticals comes down to label breadth, dosing convenience, demonstrated efficacy in labeled endpoints, and net price after rebates.

Competitor comparison factors that influence share

• Efficacy in the specific labeled endpoints.
• Adverse event profile and discontinuation rates.
• Ease of titration and administration (dose frequency).
• Contracting: payer access speed and formulary placement.
• Evidence quality: head-to-head data versus cross-trial comparisons.

What share-shift triggers most often drive mid-cycle revenue changes?

• A major payer moves the product to preferred status.
• A competitor wins a broader label or achieves superior outcomes in real-world evidence.
• A safety signal causes restricted use or tighter PA criteria.

Critical constraint: The prompt provides no list of competitors, no active ingredient, and no indication for CAVHANZA, so a fact-based competitor table cannot be produced.

What is the Orange Book status of CAVHANZA and what does it imply for launches?

Featured answer: Orange Book listings and listed patents indicate who controls exclusivity and which patents are likely to face challenges.

What to extract from Orange Book for financial modeling

A complete modeling dataset normally includes:

• NDA/BLA number
• Listed patents (composition, method-of-use, formulation)
• Patent expiration dates (and pediatric extensions)
• Regulatory exclusivities tied to the approval date

Critical constraint: No Orange Book dataset for CAVHANZA is provided. Without NDA/BLA identifiers and patent listings, status and launch implications cannot be stated.

How do FDA regulatory milestones affect the financial trajectory of CAVHANZA?

Featured answer: Regulatory milestones govern market access: approval date, label expansions, REMS requirements (if any), pediatric study requirements, and post-marketing changes.

What regulatory events typically change sales direction

• Label expansion expands eligible patient pool and improves formulary acceptance.
• Safety communications tighten prescribing and can trigger contracting changes.
• Post-approval manufacturing updates can affect supply continuity and pricing leverage.

Critical constraint: FDA approval pathway, approval date, label wording, and any regulatory actions are not provided, so a timeline cannot be constructed.

How should investors and business teams model CAVHANZA revenue trajectory?

Featured answer: CAVHANZA’s revenue model should be a patient adoption curve on top of net price, with reimbursement friction as the pacing factor.

A revenue model structure that fits cannabinoid CNS markets

• Addressable patient count = eligible diagnosis population × label fit
• Adoption curve = prescriber initiation rate × persistence × switch rate
• Net price = list price × (1 - rebate rate) × (coverage weighted by formulary tier)
• Supply and contracting = avoid stockouts and PA denials

What KPIs determine whether the trajectory improves or deteriorates?

• Share of script growth after formulary decisions
• Denial and appeal rates for prior authorization
• Persistence at 6 and 12 months
• Real-world discontinuation due to adverse events
• Average net price and rebate rate trends

Critical constraint: No sales history, price, reimbursement, or patient numbers are provided, so no numeric trajectory can be produced.

Key Takeaways

• CAVHANZA’s financial trajectory is structurally driven by label-defined patient population and net pricing after reimbursement friction.
• Patent and exclusivity events determine whether competition arrives gradually (contracting pressure) or abruptly (generic/authorized-entrant entry).
• Without NDA/BLA identification, Orange Book listings, approval date, indication, dosing form, and sales/pricing data, a quantified market forecast and exclusivity/entry timeline cannot be stated.

FAQs

1. What indication and dosage form does CAVHANZA have, and how does that change the eligible patient pool?
2. How do prior authorization and step therapy typically affect cannabinoid CNS product net sales?
3. What patents and exclusivity categories usually block generic substitution for CBD-based medicines?
4. What settlement patterns most often drive delayed generic entry for high-friction CNS drugs?
5. How can label expansions for cannabinoid products change payer coverage and prescribing behavior?

References

1. None cited.